Aligos Therapeutics Statistics
Total Valuation
ALGS has a market cap or net worth of $34.47 million. The enterprise value is -$16.09 million.
| Market Cap | 34.47M |
| Enterprise Value | -16.09M |
Important Dates
The next estimated earnings date is Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALGS has 6.19 million shares outstanding. The number of shares has increased by 52.58% in one year.
| Current Share Class | 5.39M |
| Shares Outstanding | 6.19M |
| Shares Change (YoY) | +52.58% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 1.90% |
| Owned by Institutions (%) | 29.00% |
| Float | 3.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.33 |
| Forward PS | 1.80 |
| PB Ratio | 1.08 |
| P/TBV Ratio | 1.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.56, with a Debt / Equity ratio of 0.14.
| Current Ratio | 2.56 |
| Quick Ratio | 2.35 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -121.86% and return on invested capital (ROIC) is -74.53%.
| Return on Equity (ROE) | -121.86% |
| Return on Assets (ROA) | -55.56% |
| Return on Invested Capital (ROIC) | -74.53% |
| Return on Capital Employed (ROCE) | -232.01% |
| Weighted Average Cost of Capital (WACC) | 14.86% |
| Revenue Per Employee | $57,378 |
| Profits Per Employee | -$1.10M |
| Employee Count | 82 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ALGS has paid $588,000 in taxes.
| Income Tax | 588,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.00% in the last 52 weeks. The beta is 2.27, so ALGS's price volatility has been higher than the market average.
| Beta (5Y) | 2.27 |
| 52-Week Price Change | -27.00% |
| 50-Day Moving Average | 5.83 |
| 200-Day Moving Average | 7.93 |
| Relative Strength Index (RSI) | 50.72 |
| Average Volume (20 Days) | 88,273 |
Short Selling Information
The latest short interest is 576,909, so 9.32% of the outstanding shares have been sold short.
| Short Interest | 576,909 |
| Short Previous Month | 535,177 |
| Short % of Shares Out | 9.32% |
| Short % of Float | 15.82% |
| Short Ratio (days to cover) | 4.26 |
Income Statement
In the last 12 months, ALGS had revenue of $4.71 million and -$90.32 million in losses. Loss per share was -$8.70.
| Revenue | 4.71M |
| Gross Profit | -64.87M |
| Operating Income | -95.67M |
| Pretax Income | -89.73M |
| Net Income | -90.32M |
| EBITDA | -94.59M |
| EBIT | -95.67M |
| Loss Per Share | -$8.70 |
Balance Sheet
The company has $54.91 million in cash and $4.35 million in debt, with a net cash position of $50.56 million or $8.17 per share.
| Cash & Cash Equivalents | 54.91M |
| Total Debt | 4.35M |
| Net Cash | 50.56M |
| Net Cash Per Share | $8.17 |
| Equity (Book Value) | 31.79M |
| Book Value Per Share | 5.14 |
| Working Capital | 36.31M |
Cash Flow
In the last 12 months, operating cash flow was -$84.72 million and capital expenditures -$463,000, giving a free cash flow of -$85.19 million.
| Operating Cash Flow | -84.72M |
| Capital Expenditures | -463,000 |
| Depreciation & Amortization | 1.08M |
| Net Borrowing | -76,000 |
| Free Cash Flow | -85.19M |
| FCF Per Share | -$13.77 |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,033.39% |
| Pretax Margin | -1,907.18% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALGS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -52.58% |
| Shareholder Yield | -52.58% |
| Earnings Yield | -262.04% |
| FCF Yield | -247.14% |
Analyst Forecast
The average price target for ALGS is $56.29, which is 910.59% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $56.29 |
| Price Target Difference | 910.59% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 209.97% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 19, 2024. It was a reverse split with a ratio of 1:25.
| Last Split Date | Aug 19, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
ALGS has an Altman Z-Score of -17.66 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.66 |
| Piotroski F-Score | 3 |